Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment

Parkinsonism and Related Disorders

Volumn 15, Issue SUPPL. 3, 2009, Pages

  Onofrj, Marco ^a,b   Bonanni, Laura ^a,b   Cossu, Giovanni ^c   Manca, Davide ^c   Stocchi, Fabrizio ^d   Thomas, Astrid ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c Neurology Service   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Acute akinesia; Akinetic crisis; Guillain Barr ; L Dopa gel infusion; Life threatening dyskinesias

Indexed keywords

AMANTADINE; AMANTADINE SULFATE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; CYANOCOBALAMIN; DANTROLENE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MUSCLE ENZYME; NEUROLEPTIC AGENT; ONDANSETRON; PLACEBO; STEROID;

ACUTE DISEASE; AKINESIA; ARTICLE; BRAIN DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFUSION; CONTINUOUS INFUSION; CYANOCOBALAMIN DEFICIENCY; DIAGNOSTIC ERROR; DISEASE SEVERITY; DRUG MEGADOSE; DYSAUTONOMIA; DYSKINESIA; DYSPHAGIA; EMERGENCY; GEL; GUILLAIN BARRE SYNDROME; HUMAN; HYPERTHERMIA; MENTAL HEALTH; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHY; PARKINSON DISEASE; PARKINSONISM; POLYNEUROPATHY; PRIORITY JOURNAL; QUADRIPLEGIA; VOMITING;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONIAN DISORDERS; POLYNEUROPATHIES;

EID: 71849119462     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(09)70821-1     Document Type: Article

References (46)

1. Furcht S.J., and Fahn S. Movement disorder emergencies (2005), Humana Press, Totowa, NJ
2. Kipps C.M., Fung V.S.C., Grattan-Smith P., de Moore G.M., and Morris J.G.L. Movement Disorders emergencies. Mov Disord 20 3 (2005) 322-334
3. Poston K.L., and Frucht S.J. Movement disorder emergencies. J Neurol 255 4 Suppl (2008) 2-13
4. Onofrj M., and Thomas A. Acute akinesia in Parkinson disease. Neurology 64 7 (2005) 1162-1169 12
5. Friedman J.H., Feinberg S.S., and Feldman R.C. Neuroleptic malignant-like syndrome due to L-Dopa withdrawal. Ann Neurol 16 (1984) 126
6. Granner M.A., and Wooten G.F. Neuroleptic malignant syndrome or Parkinsonism hyperpyrexia syndrome. Semin Neurol 11 (1991) 228-235
7. Meagher L.J., McKay D., Herkes G.K., and Needham M. Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy. J Clin Neurosci 13 8 (2006) 857-859
8. Takubo H., Harada T., Hashimoto T., Inaba Y., Kanazawa I., Kuno S., et al. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 9 (2003) S31-S41
9. Danielczyk W. Die Behandlung von akinetischen Krisen. Med Welt 24 (1973) 1278-1282
10. Muschard G., and Völler G.W. Wirksamkeit von Amantadinsulfat als Infusionslösung bei der Behandlung des Parkinsons Syndroms. Med Welt 24 (1973) 183-184
11. Oppel F., and Klaes H. Die Amantadin-Infusionen in der akuten Behandlung der Morbus Parkinson. Klinikarzt 10 (1981) 559-565
12. Deutsche Gesellschaft für Neurologie: Leitlinien - Parkinson-Syndrome; 4,3,4,2 Akinetische Krise. www.dgn.org/168.0html#926
13. Tanner C.M., Goetz C.G., and Klawans H.L. Autonomic nervous system disorders. In: Koller W.C. (Ed). Handbook of Parkinson's disease (1987), Marcel Dekker, New York 161-163
14. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's Disease. J Neural Transm Suppl 46 (1995) 399-409
15. Simonetto M., Ferigo L., Zanet L., Capus L., Antonutti L., Zorzon M., et al. Acute akinesia, an unusual complication in Parkinson's Disease: a case report. Neurol Sci 29 3 (2008 Jun) 181-183
16. Tackenberg B., Möller J.C., Eggert K., Sommer N., and Oertel W.H. Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine. Mov Disord 21 1 (2006) 126-127
17. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 51 Suppl 2 (1998) S25-S29
18. Stacy M., and Factor S. Rapid treatment of "off" episodes. Will this change Parkinson disease therapy?. Neurology 62 Suppl 4 (2004) S1-S2
19. Shalev A., Hermesh H., and Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 50 (1989) 18-25
20. Yamawaki Y., and Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. Rinshoshinkeigaku 31 (1991) 62-67
21. Blank J.W., and Boggs S.D. Successful treatment of an episode of malignant hyperthermia using a large dose of dantrolene. J Clin Anesthet 5 (1993) 69-72
22. Sato Y., Asoh T., Metoki N., and Satoh K. Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease. J Neurol Neurosurg Psychiatry 74 (2003) 574-576
23. Wang H.C., and Hsieh Y. Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord 16 (2001) 765-767
24. McKeith I., and Misumann U. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord 10 Suppl 1 (2004) S15-S18
25. Dickson D.W. Neuropathology of Parkinsonian disorders. In: Jankovic J., and Tolosa E. (Eds). Parkinson's disease and movement disorders. 4th edn. (2002), Lippincott Williams & Wilkins, Philadelphia, PA 256-269
26. 2+ regulation defects. Physiol Rev 76 (1996) 537-592
27. Paul-Pletzer K., Yamamoto T., Bhat M.B., Ma J., Ikemoto N., Jimenez L.S., et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 277 (2002) 34918-34923
28. Gómez-Herreros R., and Romero Alonso A. [Acute akinesia in a patient with Parkinson disease]. Med Clin (Barc) 130 4 (2008) 156
29. Dafotakis M., Sparing R., Juzek A., Block F., and Kosinski C.M. Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. J Clin Neurosci 16 2 (2009) 335-337
30. de la Fuente-Fernández R., Schulzer M., Mak E., Calne D.B., and Stoessl A.J. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 127 Pt 4 (2004) 888-899
31. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 52 (2002) 628-634
32. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 (2003) 403-414
33. Hagell P., Piccini P., Björklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 5 (2002) 627-628
34. Freed C.R., Greene P.E., Breeze R.E., Wei-Yann T., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Eng J Med 344 (2001) 710-719
35. Piccini P., Pavese N., Hagell P., Reimer J., Björklund A., Oertel W.H., et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128 Pt 12 (2005) 2977-2986
36. Bradley W.G., Daroff R.B., Fenichel G.M., and Jankovic J. Neurology in clinical practice, 5th edn. Volume I: Principles of diagnosis and management (2008), Butterworth Heinemann Elsevier 373-374
37. Jung S.K. A young onset Parkinson's patient: a case study. J Neurosci Nurs 36 5 (2004) 273-277
38. Thomas A., Iacono D., Luciano A.L., Armellino K., Di Iorio A., and Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75 1 (2004) 141-143
39. Toth C., Brown M.S., Furtado S., Suchowersky O., and Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 23 (2008) 1850-1859
40. Antonini A., Isaias I.U., Canesi M., Zibetti M., Mancini F., Manfredi L., et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 22 (2007) 1145-1149
41. Postuma R.B., and Lang A.E. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy?. Neurology 63 (2004) 886-891
42. Hadden R.D., Cornblath D.R., Hughes R.A., Zielasek J., Hartung H.P., Toyka K.V., et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 44 5 (1998) 780-788
43. Ogawara K., Kuwabara S., Mori M., Hattori T., Koga M., and Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 48 4 (2000 Oct) 624-631
44. Manca D., Cossu G., Murgia D., Molari A., Ferrigno P., Marcia E., et al. Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy. Mov Disord (2009 Sep 30) [Epub ahead of print].
45. Filippo T.S., and Holder W.D. Neurologic degeneration associated with nitrous oxide anaesthesia in patients with vitamin B12 deficiency. Arch Surg 128 (1993) 1391-1395
46. Müller T., Renger K., and Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch Neurol 61 5 (2004) 657-660